title: Lung Malignancies in HIV Infection.
abstract: Pulmonary malignancies are a major source of morbidity and mortality in HIV-infected persons. Non-AIDS-defining lung cancers (mostly non-small cell lung cancers) are now a leading cause of cancer death among HIV-infected persons. HIV-associated factors appear to affect the risk of lung cancer and may adversely impact cancer treatment and outcomes. HIV infection also may modify the potential harms and benefits of lung cancer screening with computed tomography. AIDS-defining lung malignancies include pulmonary Kaposi sarcoma and pulmonary lymphoma, both of which are less prevalent with widespread adoption of antiretroviral therapy.
authors.affiliation: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Keith
authors.initials: K
authors.lastname: Sigel
authors.affiliation: Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
authors.forename: Robert
authors.initials: R
authors.lastname: Pitts
authors.affiliation: Department of Medicine, University of Washington, Seattle, Washington.
authors.forename: Kristina
authors.initials: K
authors.lastname: Crothers
mesh_terms: D019380:Anti-HIV Agents / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications* / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000453:epidemiology / Q000209:etiology* / Q000473:pathology; D016483:Lymphoma, AIDS-Related / Q000453:epidemiology / Q000209:etiology; D008403:Mass Screening / Q000379:methods*; D012514:Sarcoma, Kaposi / Q000453:epidemiology / Q000209:etiology; D014057:Tomography, X-Ray Computed
chemical_list: D019380:Anti-HIV Agents